Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lifecore Biomedical, Inc. - Common Stock (NQ: LFCR )

6.530 -0.010 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lifecore Biomedical, Inc. - Common Stock

< Previous 1 2 Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
From The Rosen Law Firm, P.A.
Via Business Wire
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP
From Johnson Fistel, LLP
Via Business Wire
LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating Lifecore Biomedical, Inc. on Behalf of Lifecore Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)
From Kirby McInerney LLP
Via Business Wire
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Provides Business Update
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods
U.S. Department of Justice Declines Prosecution 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results
Going concern qualification is removed as a result of the $150 million new financing transaction announced last week 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Lifecore Biomedical Announces Intent to Explore Strategic Alternatives
From Lifecore Biomedical, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.